Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

NCT03115333 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT03115333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03115333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Not applicable
Overall status
Active, not recruiting
Start date
July 25, 2017
Completion date
May 7, 2027
Enrollment
146 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

gliosarcoma, recurrent glioblastoma